Tango Therapeutics, Inc.
TNGX
शेयरों में रैंक
#4543
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
शेयर मूल्य
$27.18
अंतिम समन्वयन: 2026-07-31
मार्केट कैप
$3.38B
बदलाव (1 दिन)
-1.41%
बदलाव (1 वर्ष)
202.34%
देश
US
व्यापार Tango Therapeutics, Inc. (TNGX)
श्रेणी
Healthcare
Tango Therapeutics, Inc. (TNGX) के लिए P/B अनुपात
October 2026 को P/B अनुपात TTM: 3.25
Tango Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 3.25 है। 2023 के अंत में, कंपनी का P/B अनुपात 3.70 था।
Tango Therapeutics, Inc. के लिए 2019 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
| वर्ष | P/B अनुपात | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 3.25 | 92.08% |
| 2024 | 1.69 | -54.27% |
| 2023 | 3.70 | 44.94% |
| 2022 | 2.55 | 29.49% |
| 2021 | 1.97 | -79.17% |
| 2020 | 9.46 | -18.62% |
| 2019 | 11.63 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
| कंपनी | P/B अनुपात | P/B अनुपात में अंतर | देश |
|---|---|---|---|
| 6.251 | 92.57% |
US
|
|
| 13.2547 | 308.33% |
US
|
|
| 4.208 | 29.63% |
AU
|
|
| 6.1824 | 90.46% |
NL
|
|
| - | - |
CH
|
